Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults and children ages 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer requiring systemic therapy.
LAMPGEN ANALYSIS
Why it matters
Established targeted RET inhibition as an approved option for a molecularly defined medullary thyroid cancer population.
What research teams should watch
Distinguish a RET mutation from a fusion and coordinate age-appropriate testing and longitudinal monitoring.
PRIMARY RECORDS